Top news of the week: 28.11.2022.
Pharmacology
Pre-clinical development
Finance
Medicine
Beta amyloid
Drug development
Hemispherian raises the first tranche of a Series A to fund the development of its novel cancer therapeutics https://t.co/4YXpAygadK
OpenHemispherian raises the first tranche of a Series A to fund the development of its novel cancer therapeutics
Hemispherian raises the first tranche of a Series A to fund the development of its novel cancer therapeutics - read this article along with other careers information, tips and advice on ...
RT @VivoryonNV: Our CEO, Ulrich Dauer provides his insights to recent clinical developments in the AD field in this @Labiotech_eu article. Learn why Uli believes there is a lot of progress on the horizon & what we can learn from recent trial outcomes at https://t.co/a4zqubDsUf.
OpenWhat recent mixed clinical results can teach about Alzheimer’s disease
Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons mixed fortunes in the Alzheimer’s disease field provide.
Captor Therapeutics Reports Q3 2022 Results and Provides Business UpdateLead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical Captor Therapeutics S.A. reports its financial results for the… https://t.co/Pcvma7s2R1
OpenCaptor Therapeutics Reports Q3 2022 Results and Provides Business UpdateLead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical
Captor Therapeutics Reports Q3 2022 Results and Provides Business UpdateLead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical - ...